Trial Profile

A Phase III Randomized, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 19 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sorafenib (Primary)
Indications Liver cancer
Focus Registrational; Therapeutic Use
Acronyms SHARP
Sponsors Bayer

Most Recent Events

08 Jun 2021 Results of meta analysis of Four eligible phase III studies (REFLECT, SHARP, Asia-Pac and IMbrave150) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
12 Sep 2017 Results of exploratory analysis assessing overall survival by using baseline platelet count from three studies (SHARP, AP, and RESORCE) presented at the 42nd European Society for Medical Oncology Congress
01 Sep 2017 According to a Bayer media release, data for overall survival by platelet count at baseline will be presented at the European Society for Medical Oncology (ESMO) Congress in Sep 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com